Share on StockTwits

Stock analysts at Leerink Swann decreased their price objective on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from $48.00 to $42.00 in a report issued on Friday. Leerink Swann’s price target would suggest a potential upside of 212.50% from the company’s current price.

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 13.45 on Friday. Dicerna Pharmaceuticals has a 52-week low of $13.33 and a 52-week high of $46.00. The stock has a 50-day moving average of $17.08 and a 200-day moving average of $23.81. The company’s market cap is $238.9 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Thursday, August 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.17. On average, analysts predict that Dicerna Pharmaceuticals will post $-2.27 earnings per share for the current fiscal year.

Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Wednesday, May 14th. They now have a $44.00 price target on the stock, down previously from $53.00.

Dicerna Pharmaceuticals, Inc is a biopharmaceutical company. The Company focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.